The present invention comprises a nanoparticulate composition comprising (a) a benzodiazepine having an effective average particle size of less than about 2000 nm wherein the benzodiazepine is selected from the group consisting of alprazolam brotizolam chlordiazepoxide clobazam clonazepam clorazepam demoxazepam flumazenil flurazepam halazepam midazolam nordazepam medazepam diazepam nitrazepam oxazepam midazepam prazepam quazepam triazolam temazepam loprazolam pharmaceutically acceptable salts an...

The patent application relates to chemical compounds with a basic structure selected from salicylic acid acetylsalicylic acid APHS (o-acetoxyphenylhept-2-inylsulfid) salen ligands diflunisal salsalate benorylate phenylalkanylcarbon acids (particularly fenoprofen ibuprofen ketoprofen flurbiprofen naproxen tolmetin sulindac indomethacin diclofenac carprofen etodolac ketorolac) oxicam inhibitors (particularly Tenoxicam Prioxicam Meloxicam) anthranilic acids: (particularly mefenamic acid meclofenami...

Die Patentanmeldung betrifft chemische Verbindungen mit einer Grundstruktur ausgewählt aus Salicylsäure Acetylsalicylsäure APHS (o-Acetoxyphenylhept-2-inylfulfid) Salenliganden Diflunisal Salsalat Benorylat Phenylalkanylcarbonsäuren (insbesondere Fenoprofen Ibuprofen Ketoprofen Flurbiprofen Naproxen Tolmetin Sulindac Indomethacin Diclofenac Carprofen Etodolac Ketorolac) Oxicaminhibitoren (insbesondere Tenoxicam Prioxicam Meloxicam) Anthranil-Säuren (insbesondere Mefenaminsäure Meclofenamin...

Reivindicación 1: Una formulación farmacéutica administrada por vía oral caracterizada porque comprende uno o más ingredientes farmacéuticos activos (IFA) que opcionalmente comprende sus sales complejos profármacos y metabolitos que comprende cacao en polvo y porque él uno o más IFA se eligen(n) entre IFA adecuados para absorción oral. Reivindicación 2: Una formulación de acuerdo con la reivindicación 1 caracterizada porque él uno o más ingredientes farmacéuticos activos (IFA) se selecciona(n) d...

1. A water-soluble pharmaceutical product in a solid state and true aqueous solutions of said product comprising a) a therapeutically active substance having a low aqueous solubility of less than 1x10 moles/litre and having a high binding affinity to a plasma protein - wherein the term "high binding affinity" means that more than 90% of the active substance is bound to the applied plasma protein in an aqueous medium in spontaneous equilibrium and room temperature; b) a plasma protein fraction in...